Bioporto wants to build US organization
Denmark’s Bioporto has issued new shares and raised capital to see out its new strategy on the US market. The company aims to launch its own offices and organization in the country.
BY ELIZABETH MØNSTED JOHANSEN
It was mainly a change in strategy for the US launch of Bioporto's NGAL test which spurred the Danish diagnostics group to issue new shares, raising DKK 28.14 million, in a move announced at the beginning of the week, CEO Peter Mørch Eriksen tells MedWatch.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto wraps up enrollment ahead of summer NDA
For abonnenter
BioPorto expects fast US penetration
For abonnenter
BioPorto denies rumors in the market
For abonnenter
